The Rising Demand for Skin Cancer Therapies Further Boosts the global skin cancer diagnosis & Therapeutics Market Growth

The global skin cancer diagnosis and therapeutics market are anticipated to grow at a considerable CAGR of around 7.5% during the forecast period (2021-2027). One of the major drivers of the market is the increasing demand for skin cancer therapies such as radiation therapy, chemotherapy, immunotherapy, and other drug therapy. There has been an increased adoption rate of these therapeutics among the patients, which is likely to increase the market growth. According to WHO, the rate of both non-melanoma and melanoma skin cancers has been increasing day by day. Around 3 million non-melanoma skin cancers, and 132,000 melanoma skin cancers occur across the globe. In addition to that, several government initiatives have proven to be favorable for the skin cancer diagnosis and therapeutics market. Besides, there is a lack of awareness among the patients in emerging countries about the availability of this form of treatment is a restraint of the market.

Browse the full report description of "Global Skin Cancer Diagnosis and Therapeutics Market Research By Type (Melanoma and Non-Melanoma), By Therapy (Surgery treatment, Radiotherapy, Chemotherapy, Targeted therapy, Immunotherapy, and Others), By Diagnosis (Dermatoscopy, Biopsy, Blood test, X-rays, and Others), Forecast, 2021-2027" at https://www.omrglobal.com/industry-reports/skin-cancer-diagnosis-and-therapeutics-market

 In addition, to create opportunities the key players operating in the market have been inventing new drugs with FDA approval of several new immunotherapies. For instance, In June 2020, Merck & Co., Inc. received approval for pembrolizumab for cutaneous squamous cell carcinoma from the US Food and Drug Administration (FDA). The drug is used for the treatment of a patient having metastatic cutaneous squamous cell carcinoma (CSCC) that is not treatable by surgery or radiation.

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered- 

o By Type

o By Therapy

o ByDiagnosis

• Regions Covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape – Pfizer Inc., Merck & co. Inc., Bristol Myers Squibb co., Novartis International AG, Sanofi S.A., Bausch Health Companies Inc., and others

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Skin Cancer Diagnosis and Therapeutics Market 

By Type 

• Melanoma
• Non-Melanoma

By Therapy

• Surgery treatment
• Radiotherapy
• Chemotherapy
• Targeted therapy
• Immunotherapy
• Others

By Diagnosis

• Dermatoscopy
• Biopsy
• Blood test
• X-rays
• Others

Global Skin Cancer Diagnosis and Therapeutics Market by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe 

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific 

Rest of the World

• Latin America 
• Middle East & Africa

To learn more about this report request a free sample copy @  https://www.omrglobal.com/request-sample/skin-cancer-diagnosis-and-therapeutics-market